Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Dec 21, 2013; 19(47): 9104-9110
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9104
Published online Dec 21, 2013. doi: 10.3748/wjg.v19.i47.9104
131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma
Qing He, Yong-Song Guan, Oncology Department, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Wu-Sheng Lu, Department of Vascular Surgery, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Yang Liu, Department of Psychiatry, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
An-Ren Kuang, Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: He Q and Kuang AR conceived and designed the study, and prepared the manuscript; Lu WS, Guan YS and Liu Y acquired and analyzed the data.
Correspondence to: Dr. An-Ren Kuang, Department of Nuclear Medicine, West China Hospital of Sichuan University, No. 37, Guo Xue Xiang, Chengdu 610041, Sichuan Province, China. kuanganren@263.net
Telephone: +86-28-85423270 Fax: +86-28-85423278
Received: September 4, 2013
Revised: October 8, 2013
Accepted: November 2, 2013
Published online: December 21, 2013
Processing time: 137 Days and 18.2 Hours
Revised: October 8, 2013
Accepted: November 2, 2013
Published online: December 21, 2013
Processing time: 137 Days and 18.2 Hours
Core Tip
Core tip:131I-metuximab has high affinity with a target antigen highly expressed on hepatocellular carcinoma (HCC) cells and a limited area of action. The combination of metuximab and transcatheter arterial chemoembolization had a synergistic effect in the treatment of HCC. It may represent a promising treatment modality for patients with advanced HCC, especially for those patients with multiple nodules who have a heavy tumor burden.